Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) Stock Competitors & Peer Comparison

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, IBM has a market cap of 221.9B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while IBM trades at $235.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas IBM's P/E ratio is 19.83. In terms of profitability, EKSO's ROE is -1.77%, compared to IBM's ROE of +0.34%. Regarding short-term risk, EKSO is more volatile compared to IBM. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check IBM's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ACN has a market cap of 116B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ACN trades at $189.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ACN's P/E ratio is 13.83. In terms of profitability, EKSO's ROE is -1.77%, compared to ACN's ROE of +0.25%. Regarding short-term risk, EKSO is more volatile compared to ACN. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ACN's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, INFY has a market cap of 48.9B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while INFY trades at $12.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas INFY's P/E ratio is 14.53. In terms of profitability, EKSO's ROE is -1.77%, compared to INFY's ROE of +0.33%. Regarding short-term risk, EKSO is more volatile compared to INFY. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check INFY's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, FI has a market cap of 34.3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while FI trades at $63.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas FI's P/E ratio is 9.86. In terms of profitability, EKSO's ROE is -1.77%, compared to FI's ROE of +0.11%. Regarding short-term risk, EKSO is more volatile compared to FI. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check FI's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CTSH has a market cap of 28.8B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CTSH trades at $64.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CTSH's P/E ratio is 11.62. In terms of profitability, EKSO's ROE is -1.77%, compared to CTSH's ROE of +0.15%. Regarding short-term risk, EKSO is more volatile compared to CTSH. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CTSH's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, FISV has a market cap of 28.4B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while FISV trades at $53.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas FISV's P/E ratio is 8.22. In terms of profitability, EKSO's ROE is -1.77%, compared to FISV's ROE of +0.11%. Regarding short-term risk, EKSO is more volatile compared to FISV. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check FISV's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, FIS has a market cap of 21.4B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while FIS trades at $41.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas FIS's P/E ratio is 6.87. In terms of profitability, EKSO's ROE is -1.77%, compared to FIS's ROE of +0.23%. Regarding short-term risk, EKSO is more volatile compared to FIS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check FIS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, BR has a market cap of 21.2B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while BR trades at $183.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas BR's P/E ratio is 19.05. In terms of profitability, EKSO's ROE is -1.77%, compared to BR's ROE of +0.40%. Regarding short-term risk, EKSO is more volatile compared to BR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check BR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CDW has a market cap of 18.9B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CDW trades at $147.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CDW's P/E ratio is 14.11. In terms of profitability, EKSO's ROE is -1.77%, compared to CDW's ROE of +0.43%. Regarding short-term risk, EKSO is more volatile compared to CDW. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CDW's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, WIT has a market cap of 18B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while WIT trades at $1.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas WIT's P/E ratio is 13.46. In terms of profitability, EKSO's ROE is -1.77%, compared to WIT's ROE of +0.15%. Regarding short-term risk, EKSO is more volatile compared to WIT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check WIT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, LDOS has a market cap of 17.7B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while LDOS trades at $140.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas LDOS's P/E ratio is 11.52. In terms of profitability, EKSO's ROE is -1.77%, compared to LDOS's ROE of +0.28%. Regarding short-term risk, EKSO is more volatile compared to LDOS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check LDOS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, GIB has a market cap of 16B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while GIB trades at $74.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas GIB's P/E ratio is 12.00. In terms of profitability, EKSO's ROE is -1.77%, compared to GIB's ROE of +0.17%. Regarding short-term risk, EKSO is more volatile compared to GIB. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check GIB's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CACI has a market cap of 13.9B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CACI trades at $628.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CACI's P/E ratio is 21.08. In terms of profitability, EKSO's ROE is -1.77%, compared to CACI's ROE of +0.13%. Regarding short-term risk, EKSO is more volatile compared to CACI. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CACI's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, IT has a market cap of 13.2B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while IT trades at $198.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas IT's P/E ratio is 13.65. In terms of profitability, EKSO's ROE is -1.77%, compared to IT's ROE of +4.01%. Regarding short-term risk, EKSO is more volatile compared to IT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check IT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, WSE has a market cap of 13B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while WSE trades at $13.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas WSE's P/E ratio is 13.30. In terms of profitability, EKSO's ROE is -1.77%, compared to WSE's ROE of +0.26%. Regarding short-term risk, EKSO is more volatile compared to WSE. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check WSE's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, IREN has a market cap of 12.7B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while IREN trades at $35.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas IREN's P/E ratio is -24.62. In terms of profitability, EKSO's ROE is -1.77%, compared to IREN's ROE of +0.03%. Regarding short-term risk, EKSO is more volatile compared to IREN. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check IREN's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, JKHY has a market cap of 12.1B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while JKHY trades at $169.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas JKHY's P/E ratio is 23.73. In terms of profitability, EKSO's ROE is -1.77%, compared to JKHY's ROE of +0.23%. Regarding short-term risk, EKSO is more volatile compared to JKHY. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check JKHY's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, APLD has a market cap of 7.3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while APLD trades at $25.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas APLD's P/E ratio is -36.20. In terms of profitability, EKSO's ROE is -1.77%, compared to APLD's ROE of -0.17%. Regarding short-term risk, EKSO is more volatile compared to APLD. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check APLD's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, INGM has a market cap of 6.6B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while INGM trades at $28.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas INGM's P/E ratio is 9.44. In terms of profitability, EKSO's ROE is -1.77%, compared to INGM's ROE of +0.10%. Regarding short-term risk, EKSO is more volatile compared to INGM. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check INGM's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, GDS has a market cap of 6.5B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while GDS trades at $33.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas GDS's P/E ratio is 13.47. In terms of profitability, EKSO's ROE is -1.77%, compared to GDS's ROE of +0.13%. Regarding short-term risk, EKSO is more volatile compared to GDS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check GDS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, G has a market cap of 6.4B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while G trades at $38.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas G's P/E ratio is 10.01. In terms of profitability, EKSO's ROE is -1.77%, compared to G's ROE of +0.23%. Regarding short-term risk, EKSO is more volatile compared to G. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check G's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CIFR has a market cap of 6.2B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CIFR trades at $15.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CIFR's P/E ratio is -5.30. In terms of profitability, EKSO's ROE is -1.77%, compared to CIFR's ROE of -1.56%. Regarding short-term risk, EKSO is more volatile compared to CIFR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CIFR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, EPAM has a market cap of 6B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while EPAM trades at $114.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas EPAM's P/E ratio is 9.13. In terms of profitability, EKSO's ROE is -1.77%, compared to EPAM's ROE of +0.11%. Regarding short-term risk, EKSO is more volatile compared to EPAM. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check EPAM's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, EXLS has a market cap of 5.8B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while EXLS trades at $38.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas EXLS's P/E ratio is 18.73. In terms of profitability, EKSO's ROE is -1.77%, compared to EXLS's ROE of +0.28%. Regarding short-term risk, EKSO is more volatile compared to EXLS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check EXLS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SAIC has a market cap of 5.3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SAIC trades at $125.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SAIC's P/E ratio is 11.31. In terms of profitability, EKSO's ROE is -1.77%, compared to SAIC's ROE of +0.27%. Regarding short-term risk, EKSO is more volatile compared to SAIC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SAIC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, PSN has a market cap of 5.2B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while PSN trades at $49.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas PSN's P/E ratio is 20.94. In terms of profitability, EKSO's ROE is -1.77%, compared to PSN's ROE of +0.06%. Regarding short-term risk, EKSO is more volatile compared to PSN. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check PSN's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, NSIT has a market cap of 4.7B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while NSIT trades at $155.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas NSIT's P/E ratio is 12.83. In terms of profitability, EKSO's ROE is -1.77%, compared to NSIT's ROE of +0.13%. Regarding short-term risk, EKSO is more volatile compared to NSIT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check NSIT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, NCR has a market cap of 3.8B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while NCR trades at $27.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas NCR's P/E ratio is 49.24. In terms of profitability, EKSO's ROE is -1.77%, compared to NCR's ROE of +0.17%. Regarding short-term risk, EKSO is more volatile compared to NCR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check NCR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, WNS has a market cap of 3.3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while WNS trades at $76.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas WNS's P/E ratio is 21.36. In terms of profitability, EKSO's ROE is -1.77%, compared to WNS's ROE of +0.09%. Regarding short-term risk, EKSO is more volatile compared to WNS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check WNS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CSQR has a market cap of 3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CSQR trades at $19.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CSQR's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to CSQR's ROE of N/A. Regarding short-term risk, EKSO is more volatile compared to CSQR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CSQR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, KD has a market cap of 2.9B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while KD trades at $13.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas KD's P/E ratio is 13.80. In terms of profitability, EKSO's ROE is -1.77%, compared to KD's ROE of +0.29%. Regarding short-term risk, EKSO is more volatile compared to KD. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check KD's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, PRFT has a market cap of 2.7B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while PRFT trades at $75.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas PRFT's P/E ratio is 36.34. In terms of profitability, EKSO's ROE is -1.77%, compared to PRFT's ROE of +0.21%. Regarding short-term risk, EKSO is more volatile compared to PRFT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check PRFT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, KEEL has a market cap of 2.1B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while KEEL trades at $3.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas KEEL's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to KEEL's ROE of -0.90%. Regarding short-term risk, EKSO is more volatile compared to KEEL. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check KEEL's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, FORTY has a market cap of 2B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while FORTY trades at $128.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas FORTY's P/E ratio is 30.54. In terms of profitability, EKSO's ROE is -1.77%, compared to FORTY's ROE of +0.54%. Regarding short-term risk, EKSO is more volatile compared to FORTY. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check FORTY's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, INOD has a market cap of 1.8B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while INOD trades at $56.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas INOD's P/E ratio is 50.98. In terms of profitability, EKSO's ROE is -1.77%, compared to INOD's ROE of +0.38%. Regarding short-term risk, EKSO is more volatile compared to INOD. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check INOD's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SHAZ has a market cap of 1.8B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SHAZ trades at $52.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SHAZ's P/E ratio is -1.72. In terms of profitability, EKSO's ROE is -1.77%, compared to SHAZ's ROE of -1.57%. Regarding short-term risk, EKSO is more volatile compared to SHAZ. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SHAZ's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, VNET has a market cap of 1.8B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while VNET trades at $6.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas VNET's P/E ratio is -5.50. In terms of profitability, EKSO's ROE is -1.77%, compared to VNET's ROE of -0.47%. Regarding short-term risk, EKSO is more volatile compared to VNET. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check VNET's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, DXC has a market cap of 1.8B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while DXC trades at $11.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas DXC's P/E ratio is 3.45. In terms of profitability, EKSO's ROE is -1.77%, compared to DXC's ROE of +0.04%. Regarding short-term risk, EKSO is more volatile compared to DXC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check DXC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CNXC has a market cap of 1.8B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CNXC trades at $29.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CNXC's P/E ratio is 2.68. In terms of profitability, EKSO's ROE is -1.77%, compared to CNXC's ROE of -0.42%. Regarding short-term risk, EKSO is more volatile compared to CNXC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CNXC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, GLOB has a market cap of 1.7B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while GLOB trades at $40.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas GLOB's P/E ratio is 6.64. In terms of profitability, EKSO's ROE is -1.77%, compared to GLOB's ROE of +0.05%. Regarding short-term risk, EKSO is more volatile compared to GLOB. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check GLOB's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, BBAI has a market cap of 1.5B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while BBAI trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas BBAI's P/E ratio is -4.44. In terms of profitability, EKSO's ROE is -1.77%, compared to BBAI's ROE of -0.12%. Regarding short-term risk, EKSO is more volatile compared to BBAI. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check BBAI's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, TWKS has a market cap of 1.4B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while TWKS trades at $4.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas TWKS's P/E ratio is -12.08. In terms of profitability, EKSO's ROE is -1.77%, compared to TWKS's ROE of -0.09%. Regarding short-term risk, EKSO is more volatile compared to TWKS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check TWKS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, MGRT has a market cap of 1.4B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while MGRT trades at $99.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas MGRT's P/E ratio is 589.71. In terms of profitability, EKSO's ROE is -1.77%, compared to MGRT's ROE of +0.21%. Regarding short-term risk, EKSO is more volatile compared to MGRT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check MGRT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, EFOR has a market cap of 1.3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while EFOR trades at $31.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas EFOR's P/E ratio is 7.39. In terms of profitability, EKSO's ROE is -1.77%, compared to EFOR's ROE of +0.05%. Regarding short-term risk, EKSO is more volatile compared to EFOR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check EFOR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, BITF has a market cap of 1.3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while BITF trades at $2.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas BITF's P/E ratio is -5.68. In terms of profitability, EKSO's ROE is -1.77%, compared to BITF's ROE of -0.90%. Regarding short-term risk, EKSO is more volatile compared to BITF. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check BITF's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, BTCM has a market cap of 1.3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while BTCM trades at $1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas BTCM's P/E ratio is -0.53. In terms of profitability, EKSO's ROE is -1.77%, compared to BTCM's ROE of -0.32%. Regarding short-term risk, EKSO is more volatile compared to BTCM. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check BTCM's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CLVT has a market cap of 1.3B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CLVT trades at $2.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CLVT's P/E ratio is 2.74. In terms of profitability, EKSO's ROE is -1.77%, compared to CLVT's ROE of -0.07%. Regarding short-term risk, EKSO is more volatile compared to CLVT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CLVT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, VYX has a market cap of 1.2B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while VYX trades at $8.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas VYX's P/E ratio is 9.87. In terms of profitability, EKSO's ROE is -1.77%, compared to VYX's ROE of +0.07%. Regarding short-term risk, EKSO is more volatile compared to VYX. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check VYX's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ASGN has a market cap of 895M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ASGN trades at $20.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ASGN's P/E ratio is 9.32. In terms of profitability, EKSO's ROE is -1.77%, compared to ASGN's ROE of +0.05%. Regarding short-term risk, EKSO is more volatile compared to ASGN. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ASGN's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SLAI has a market cap of 880.1M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SLAI trades at $3.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SLAI's P/E ratio is -1.40. In terms of profitability, EKSO's ROE is -1.77%, compared to SLAI's ROE of -0.83%. Regarding short-term risk, EKSO is less volatile compared to SLAI. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check SLAI's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, MGIC has a market cap of 853.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while MGIC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas MGIC's P/E ratio is 21.20. In terms of profitability, EKSO's ROE is -1.77%, compared to MGIC's ROE of +0.11%. Regarding short-term risk, EKSO is more volatile compared to MGIC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check MGIC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CTLP has a market cap of 825.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CTLP trades at $11.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CTLP's P/E ratio is 280.00. In terms of profitability, EKSO's ROE is -1.77%, compared to CTLP's ROE of +0.01%. Regarding short-term risk, EKSO is more volatile compared to CTLP. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CTLP's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, NABL has a market cap of 790.2M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while NABL trades at $4.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas NABL's P/E ratio is 10.76. In terms of profitability, EKSO's ROE is -1.77%, compared to NABL's ROE of -0.01%. Regarding short-term risk, EKSO is more volatile compared to NABL. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check NABL's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, HIVE has a market cap of 759.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while HIVE trades at $2.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas HIVE's P/E ratio is -2.27. In terms of profitability, EKSO's ROE is -1.77%, compared to HIVE's ROE of -0.60%. Regarding short-term risk, EKSO is more volatile compared to HIVE. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check HIVE's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, TASK has a market cap of 756.9M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while TASK trades at $8.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas TASK's P/E ratio is 5.59. In terms of profitability, EKSO's ROE is -1.77%, compared to TASK's ROE of +0.25%. Regarding short-term risk, EKSO is more volatile compared to TASK. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check TASK's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CLVT-PA has a market cap of 755.5M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CLVT-PA trades at $4.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CLVT-PA's P/E ratio is -7.93. In terms of profitability, EKSO's ROE is -1.77%, compared to CLVT-PA's ROE of -0.07%. Regarding short-term risk, EKSO is more volatile compared to CLVT-PA. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CLVT-PA's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, WYFI has a market cap of 685.4M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while WYFI trades at $17.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas WYFI's P/E ratio is -10.54. In terms of profitability, EKSO's ROE is -1.77%, compared to WYFI's ROE of -0.09%. Regarding short-term risk, EKSO is more volatile compared to WYFI. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check WYFI's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, BBAI-WT has a market cap of 669.7M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while BBAI-WT trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas BBAI-WT's P/E ratio is -0.08. In terms of profitability, EKSO's ROE is -1.77%, compared to BBAI-WT's ROE of -0.12%. Regarding short-term risk, EKSO is less volatile compared to BBAI-WT. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check BBAI-WT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, VRRM has a market cap of 666.9M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while VRRM trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas VRRM's P/E ratio is 3.38. In terms of profitability, EKSO's ROE is -1.77%, compared to VRRM's ROE of +0.15%. Regarding short-term risk, EKSO is more volatile compared to VRRM. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check VRRM's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, GDYN has a market cap of 646.6M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while GDYN trades at $7.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas GDYN's P/E ratio is 20.97. In terms of profitability, EKSO's ROE is -1.77%, compared to GDYN's ROE of +0.01%. Regarding short-term risk, EKSO is more volatile compared to GDYN. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check GDYN's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, PHLT has a market cap of 611.6M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while PHLT trades at $7.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas PHLT's P/E ratio is -775.00. In terms of profitability, EKSO's ROE is -1.77%, compared to PHLT's ROE of +0.02%. Regarding short-term risk, EKSO is more volatile compared to PHLT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check PHLT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, IBEX has a market cap of 510.4M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while IBEX trades at $38.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas IBEX's P/E ratio is 10.74. In terms of profitability, EKSO's ROE is -1.77%, compared to IBEX's ROE of +0.32%. Regarding short-term risk, EKSO is more volatile compared to IBEX. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check IBEX's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ALIT has a market cap of 370.4M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ALIT trades at $14.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ALIT's P/E ratio is 5.83. In terms of profitability, EKSO's ROE is -1.77%, compared to ALIT's ROE of -1.59%. Regarding short-term risk, EKSO is more volatile compared to ALIT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ALIT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, TLS has a market cap of 358.4M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while TLS trades at $4.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas TLS's P/E ratio is 26.61. In terms of profitability, EKSO's ROE is -1.77%, compared to TLS's ROE of -0.16%. Regarding short-term risk, EKSO is more volatile compared to TLS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check TLS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, HCKT has a market cap of 285.6M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while HCKT trades at $11.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas HCKT's P/E ratio is 7.82. In terms of profitability, EKSO's ROE is -1.77%, compared to HCKT's ROE of +0.22%. Regarding short-term risk, EKSO is more volatile compared to HCKT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check HCKT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CNDT has a market cap of 266.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CNDT trades at $1.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CNDT's P/E ratio is -4.53. In terms of profitability, EKSO's ROE is -1.77%, compared to CNDT's ROE of -0.30%. Regarding short-term risk, EKSO is more volatile compared to CNDT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CNDT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, BULLZ has a market cap of 260.4M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while BULLZ trades at $1.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas BULLZ's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to BULLZ's ROE of +0.04%. Regarding short-term risk, EKSO is less volatile compared to BULLZ. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check BULLZ's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, TSSI has a market cap of 228.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while TSSI trades at $8.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas TSSI's P/E ratio is 16.63. In terms of profitability, EKSO's ROE is -1.77%, compared to TSSI's ROE of +0.19%. Regarding short-term risk, EKSO is more volatile compared to TSSI. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check TSSI's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, UIS has a market cap of 196.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while UIS trades at $2.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas UIS's P/E ratio is 3.25. In terms of profitability, EKSO's ROE is -1.77%, compared to UIS's ROE of +1.35%. Regarding short-term risk, EKSO is more volatile compared to UIS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check UIS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SRT has a market cap of 178.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SRT trades at $4.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SRT's P/E ratio is -6.60. In terms of profitability, EKSO's ROE is -1.77%, compared to SRT's ROE of -0.00%. Regarding short-term risk, EKSO is more volatile compared to SRT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SRT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, LAWR has a market cap of 172.4M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while LAWR trades at $3.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas LAWR's P/E ratio is -53.57. In terms of profitability, EKSO's ROE is -1.77%, compared to LAWR's ROE of +1.39%. Regarding short-term risk, EKSO is more volatile compared to LAWR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check LAWR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, DAVA has a market cap of 171.4M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while DAVA trades at $3.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas DAVA's P/E ratio is 4.00. In terms of profitability, EKSO's ROE is -1.77%, compared to DAVA's ROE of -0.88%. Regarding short-term risk, EKSO is more volatile compared to DAVA. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check DAVA's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CTG has a market cap of 169M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CTG trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CTG's P/E ratio is 350.00. In terms of profitability, EKSO's ROE is -1.77%, compared to CTG's ROE of +0.07%. Regarding short-term risk, EKSO is more volatile compared to CTG. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CTG's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, KORE has a market cap of 163M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while KORE trades at $9.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas KORE's P/E ratio is -4.97. In terms of profitability, EKSO's ROE is -1.77%, compared to KORE's ROE of +0.48%. Regarding short-term risk, EKSO is more volatile compared to KORE. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check KORE's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ALYA has a market cap of 110.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ALYA trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ALYA's P/E ratio is -3.42. In terms of profitability, EKSO's ROE is -1.77%, compared to ALYA's ROE of -0.09%. Regarding short-term risk, EKSO is more volatile compared to ALYA. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ALYA's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ZENA has a market cap of 105.7M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ZENA trades at $1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ZENA's P/E ratio is -1.06. In terms of profitability, EKSO's ROE is -1.77%, compared to ZENA's ROE of -1.21%. Regarding short-term risk, EKSO is more volatile compared to ZENA. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ZENA's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, YB has a market cap of 103.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while YB trades at $13.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas YB's P/E ratio is 3.12. In terms of profitability, EKSO's ROE is -1.77%, compared to YB's ROE of +0.44%. Regarding short-term risk, EKSO is more volatile compared to YB. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check YB's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, WYY has a market cap of 97.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while WYY trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas WYY's P/E ratio is -75.69. In terms of profitability, EKSO's ROE is -1.77%, compared to WYY's ROE of -0.11%. Regarding short-term risk, EKSO is more volatile compared to WYY. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check WYY's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CSPI has a market cap of 82M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CSPI trades at $8.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CSPI's P/E ratio is -116.29. In terms of profitability, EKSO's ROE is -1.77%, compared to CSPI's ROE of -0.02%. Regarding short-term risk, EKSO is more volatile compared to CSPI. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CSPI's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, TTEC has a market cap of 68.1M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while TTEC trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas TTEC's P/E ratio is 1.46. In terms of profitability, EKSO's ROE is -1.77%, compared to TTEC's ROE of -1.62%. Regarding short-term risk, EKSO is more volatile compared to TTEC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check TTEC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CHRN has a market cap of 66.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CHRN trades at $18.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CHRN's P/E ratio is -3.30. In terms of profitability, EKSO's ROE is -1.77%, compared to CHRN's ROE of N/A. Regarding short-term risk, EKSO is less volatile compared to CHRN. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check CHRN's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, QXL has a market cap of 60.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while QXL trades at $4.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas QXL's P/E ratio is -90.50. In terms of profitability, EKSO's ROE is -1.77%, compared to QXL's ROE of -0.14%. Regarding short-term risk, EKSO is more volatile compared to QXL. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check QXL's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CTM has a market cap of 56.9M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CTM trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CTM's P/E ratio is -45.98. In terms of profitability, EKSO's ROE is -1.77%, compared to CTM's ROE of -0.06%. Regarding short-term risk, EKSO is more volatile compared to CTM. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CTM's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SIFYR has a market cap of 44.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SIFYR trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SIFYR's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to SIFYR's ROE of N/A. Regarding short-term risk, EKSO is less volatile compared to SIFYR. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check SIFYR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SAIH has a market cap of 43.5M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SAIH trades at $23.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SAIH's P/E ratio is -4.32. In terms of profitability, EKSO's ROE is -1.77%, compared to SAIH's ROE of -0.68%. Regarding short-term risk, EKSO is more volatile compared to SAIH. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SAIH's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, JFU has a market cap of 33.9M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while JFU trades at $2.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas JFU's P/E ratio is 616.95. In terms of profitability, EKSO's ROE is -1.77%, compared to JFU's ROE of +0.04%. Regarding short-term risk, EKSO is more volatile compared to JFU. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check JFU's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CLPS has a market cap of 32.2M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CLPS trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CLPS's P/E ratio is -4.56. In terms of profitability, EKSO's ROE is -1.77%, compared to CLPS's ROE of -0.12%. Regarding short-term risk, EKSO is more volatile compared to CLPS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CLPS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CHOW has a market cap of 22.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CHOW trades at $0.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CHOW's P/E ratio is -6.99. In terms of profitability, EKSO's ROE is -1.77%, compared to CHOW's ROE of -0.58%. Regarding short-term risk, EKSO is less volatile compared to CHOW. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check CHOW's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ALAR has a market cap of 11.9M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ALAR trades at $1.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ALAR's P/E ratio is 2.66. In terms of profitability, EKSO's ROE is -1.77%, compared to ALAR's ROE of +0.04%. Regarding short-term risk, EKSO is more volatile compared to ALAR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ALAR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, GLE has a market cap of 11.5M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while GLE trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas GLE's P/E ratio is -7.19. In terms of profitability, EKSO's ROE is -1.77%, compared to GLE's ROE of +0.20%. Regarding short-term risk, EKSO is more volatile compared to GLE. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check GLE's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SGLB has a market cap of 11.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SGLB trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SGLB's P/E ratio is -1.37. In terms of profitability, EKSO's ROE is -1.77%, compared to SGLB's ROE of -2.65%. Regarding short-term risk, EKSO is more volatile compared to SGLB. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SGLB's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, LZMH has a market cap of 10.1M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while LZMH trades at $1.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas LZMH's P/E ratio is -0.38. In terms of profitability, EKSO's ROE is -1.77%, compared to LZMH's ROE of -3.05%. Regarding short-term risk, EKSO is more volatile compared to LZMH. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check LZMH's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ARBB has a market cap of 7.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ARBB trades at $4.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ARBB's P/E ratio is -0.58. In terms of profitability, EKSO's ROE is -1.77%, compared to ARBB's ROE of -0.07%. Regarding short-term risk, EKSO is more volatile compared to ARBB. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ARBB's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, TDTH has a market cap of 7.3M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while TDTH trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas TDTH's P/E ratio is -0.26. In terms of profitability, EKSO's ROE is -1.77%, compared to TDTH's ROE of +3.18%. Regarding short-term risk, EKSO is more volatile compared to TDTH. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check TDTH's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, DTST has a market cap of 6.6M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while DTST trades at $3.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas DTST's P/E ratio is 43.71. In terms of profitability, EKSO's ROE is -1.77%, compared to DTST's ROE of +0.71%. Regarding short-term risk, EKSO is more volatile compared to DTST. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check DTST's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, VEEA has a market cap of 5.7M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while VEEA trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas VEEA's P/E ratio is -1.29. In terms of profitability, EKSO's ROE is -1.77%, compared to VEEA's ROE of +51.66%. Regarding short-term risk, EKSO is more volatile compared to VEEA. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check VEEA's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, DAIC has a market cap of 5.6M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while DAIC trades at $4.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas DAIC's P/E ratio is -0.10. In terms of profitability, EKSO's ROE is -1.77%, compared to DAIC's ROE of +37.71%. Regarding short-term risk, EKSO is less volatile compared to DAIC. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check DAIC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CYCU has a market cap of 5.2M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CYCU trades at $3.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CYCU's P/E ratio is -0.44. In terms of profitability, EKSO's ROE is -1.77%, compared to CYCU's ROE of -0.71%. Regarding short-term risk, EKSO is less volatile compared to CYCU. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check CYCU's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Technology sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, VEEAW has a market cap of 4.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while VEEAW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas VEEAW's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to VEEAW's ROE of +51.66%. Regarding short-term risk, EKSO is more volatile compared to VEEAW. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check VEEAW's competition here